American Journal of Gastroenterology最新文献

{"title":"Correction to: Gastric Plexiform Fibromyxoma Associated With Secondary Hypertension: A Case Report (S5145).","authors":"Megan Costello, Lavina Thadani, Vinay Jahagirdar, Erin Algeo, Jason Singh, John Campbell","doi":"10.14309/ajg.0000000000003316","DOIUrl":"https://doi.org/10.14309/ajg.0000000000003316","url":null,"abstract":"","PeriodicalId":7608,"journal":{"name":"American Journal of Gastroenterology","volume":" ","pages":""},"PeriodicalIF":8.0,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143490546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of 1 L polyethylene glycol plus ascorbic acid with linaclotide versus senna for bowel preparation: A multicenter, endoscopist-blinded, randomized controlled trial (Apple trial).","authors":"Natsumi Maeda, Akira Higashimori, Daijiro Kabata, Ikki Yamamoto, Tsuyoshi Yanagida, Daiyu Kin, Yuji Matsumoto, Rieko Nakata, Atsushi Hashimoto, Akinari Sawada, Hirotsugu Maruyama, Junichi Okamoto, Takayuki Katsuno, Yuji Nadatani, Masaki Ominami, Shusei Fukunaga, Kenichi Morimoto, Shuhei Hosomi, Fumio Tanaka, Masami Nakatani, Koichi Taira, Eiji Sasaki, Takashi Fukuda, Keiko Ota, Hisako Yoshida, Toshio Watanabe, Yasuhiro Fujiwara","doi":"10.14309/ajg.0000000000003370","DOIUrl":"https://doi.org/10.14309/ajg.0000000000003370","url":null,"abstract":"<p><strong>Objectives: </strong>No bowel preparation for colonoscopy achieves optimal efficacy and tolerability. Combining polyethylene glycol plus ascorbic acid (PEG-Asc) with adjuvants has been explored to enhance cleansing efficacy and reduce the required volume. This study aimed to evaluate whether adding 0.5 mg linaclotide to 1-L PEG-Asc (1 L-PEG/AL) improves superior cleansing compared to adding 24 mg senna (1 L-PEG/AS), which we previously reported to be non-inferior to the standard regimen of 2 L PEG-Asc.</p><p><strong>Methods: </strong>A multicenter, endoscopist-blinded, randomized controlled trial was conducted at five centers in Japan with outpatients scheduled for colonoscopy. The primary outcome was adequate bowel preparation (BP), evaluated using the Boston Bowel Preparation Scale. Analyses were stratified based on low- and high-risk groups for inadequate BP.</p><p><strong>Results: </strong>Between April 2022 and April 2023, 1,464 patients were randomized to the 1L-PEG/AL (n=733) or 1L-PEG/AS (n=731). The 1L-PEG/AL demonstrated higher adequate BP rates (92% vs. 86%, P=0.001) compared to 1L-PEG/AS. Both groups experienced similar adverse events and expressed high willingness for repeat BP (83% vs. 81%, P=0.49). In high-risk patients (n=892), 1L-PEG/AL had significantly higher adequate BP rates (94% vs. 86%, P<0.001), whereas rates were comparably high in low-risk patients (n=539) (94% vs. 94%, P=0.66).</p><p><strong>Conclusions: </strong>The linaclotide regimen was superior to the senna regimen in terms of BP efficacy without reducing tolerability. It can be a promising new option for BP, especially in patients at a high-risk of inadequate BP.</p>","PeriodicalId":7608,"journal":{"name":"American Journal of Gastroenterology","volume":" ","pages":""},"PeriodicalIF":8.0,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143490484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Spine and Sacroiliac Joint Involvement in Newly Diagnosed Patients With Inflammatory Bowel Disease: Clinical and MRI Findings From a Population-Based Cohort.","authors":"Chen Ju Fu, Huan-Wu Chen, James Cheng-Chung Wei","doi":"10.14309/ajg.0000000000003340","DOIUrl":"https://doi.org/10.14309/ajg.0000000000003340","url":null,"abstract":"","PeriodicalId":7608,"journal":{"name":"American Journal of Gastroenterology","volume":" ","pages":""},"PeriodicalIF":8.0,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143514397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ileocecal Tuberculosis in a Patient Receiving Antitumor Necrosis Factor Treatment.","authors":"Myriam Ayari, Sarrah Ben Azouz, Sarra Ben Rejeb, Taieb Jomni","doi":"10.14309/ajg.0000000000003371","DOIUrl":"10.14309/ajg.0000000000003371","url":null,"abstract":"","PeriodicalId":7608,"journal":{"name":"American Journal of Gastroenterology","volume":" ","pages":""},"PeriodicalIF":8.0,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143514395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patterns of Hepatitis B Virus Viremia Change and Hepatitis B Surface Antigen Loss Rate in Patients Without Retreatment Within 2 Years After Entecavir or Tenofovir Cessation.","authors":"Chien-Hung Chen, Wei-Chen Tai, Tsung-Hui Hu, Jing-Houng Wang, Chao-Hung Hung, Sheng-Nan Lu","doi":"10.14309/ajg.0000000000003372","DOIUrl":"10.14309/ajg.0000000000003372","url":null,"abstract":"<p><strong>Introduction: </strong>This study investigated the patterns of hepatitis B virus (HBV) viremia change and hepatitis B surface antigen (HBsAg) loss rate without retreatment within 2 years after nucleos(t)ide analog (NA) cessation.</p><p><strong>Methods: </strong>We enrolled 481 patients who did not receive retreatment in the first 2 years after entecavir or tenofovir disoproxil fumarate cessation.</p><p><strong>Results: </strong>Group I was defined as persistent HBV DNA <2,000 IU/mL and normal alanine transaminase < 40 U/mL (inactive phase); Group II and Group III, as HBV DNA >2,000 IU/mL and ALT <40 U/L (Group II) or alanine transaminase 40-80 IU/mL (Group III); and Group IV, as HBV DNA >2,000 IU/mL and ALT>80 U/mL (active phase). Of the 242 Group I patients, 205 (84.7%) remained in the same group and 22 (9.1%) transitioned to active phase beyond the first 2 years. Of the 239 Group II, III, and IV patients, 33%, 28.8%, and 31.1% patients transitioned to inactive phase beyond the first 2 years, respectively. Of the 239 patients who achieved HBsAg <150 vs ≧150 IU/mL at the end of treatment, the transition to inactive phase and HBsAg loss rates at year 5 after NA cessation were 57.2% vs 16.1% ( P < 0.001) and 25.4% vs 4.7%, respectively ( P = 0.001). The 10-year HBsAg loss rate after NA cessation for patients in Group I who remained in inactive phase, and Groups II + III and Group IV patients who transitioned to inactive phase were 57.7%, 45.4%, and 55.1% ( P = 0.404), respectively.</p><p><strong>Discussion: </strong>Patients who remained or transitioned to the inactive phase had a high HBsAg loss rate without retreatment within 2 years after NA cessation.</p>","PeriodicalId":7608,"journal":{"name":"American Journal of Gastroenterology","volume":" ","pages":""},"PeriodicalIF":8.0,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143490492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Review of the Modified Multiplier of SES-CD (MM-SES-CD) and How to Use in Clinical Trials and Practice.","authors":"Peter W Huan, Akash Mehta, Emily C L Wong, Parambir S Dulai, John K Marshall, Walter Reinisch, Neeraj Narula","doi":"10.14309/ajg.0000000000003373","DOIUrl":"https://doi.org/10.14309/ajg.0000000000003373","url":null,"abstract":"<p><p>Endoscopic evaluation is valuable in the diagnosis, assessment, and management of Crohn's Disease. The Simple Endoscopic Score for Crohn's Disease (SES-CD) was created using a uniform, linear scoring scale of 0-3 for each of its four parameters at five anatomical locations and was designed to accurately indicate disease severity rather than predict disease progression. There is evidence to suggest all disease segments and parameters of the SES-CD do not have equal prognostic value for likelihood of achieving endoscopic remission (ER). The Modified Multiplier Simple Endoscopic Score for Crohn's Disease (MM-SES-CD), developed by multivariable logistic regression modelling, weighs the individual parameters of the SES-CD including disease distribution based on their prognostic values for achieving ER. The objective of this qualitative review is to provide guidance to clinicians and clinical trialists for how to use and interpret the MM-SES-CD.</p>","PeriodicalId":7608,"journal":{"name":"American Journal of Gastroenterology","volume":" ","pages":""},"PeriodicalIF":8.0,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143490539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Addressing Follow-up Limitations in Endoscopic Submucosal Dissection Research.","authors":"Xin Zhou, Yaling Li, Jun Li","doi":"10.14309/ajg.0000000000003344","DOIUrl":"https://doi.org/10.14309/ajg.0000000000003344","url":null,"abstract":"","PeriodicalId":7608,"journal":{"name":"American Journal of Gastroenterology","volume":" ","pages":""},"PeriodicalIF":8.0,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143490542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to Zhou et al.","authors":"Gro Askgaard, Peter Jepsen, Morten Daniel Jensen, Anna Emilie Kann, Joanne Morling, Frederik Kraglund, Tim Card, Colin Crooks, Joe West","doi":"10.14309/ajg.0000000000003305","DOIUrl":"https://doi.org/10.14309/ajg.0000000000003305","url":null,"abstract":"","PeriodicalId":7608,"journal":{"name":"American Journal of Gastroenterology","volume":" ","pages":""},"PeriodicalIF":8.0,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143447998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metastatic Urothelial Carcinoma Detected by Colonoscopy During an Evaluation for Diarrhea.","authors":"Queralt Herms, Guillem Soy, Carla Fuster-Anglada, Àngels Ginès, Joan Llach","doi":"10.14309/ajg.0000000000003363","DOIUrl":"10.14309/ajg.0000000000003363","url":null,"abstract":"","PeriodicalId":7608,"journal":{"name":"American Journal of Gastroenterology","volume":" ","pages":""},"PeriodicalIF":8.0,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143439831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Contemporary Landscape of Medical Technology in Gastroenterology Between 2013 and 2023.","authors":"Megan M Hennessey, Shan Xue, Rebecca Z Strigenz, Pamela Bagley, Eric D Shah","doi":"10.14309/ajg.0000000000003359","DOIUrl":"10.14309/ajg.0000000000003359","url":null,"abstract":"<p><p>Medical technology in gastroenterology spans devices, point-of-care diagnostics, digital health, and artificial intelligence. We conducted a narrative review of US Food and Drug Administration (FDA)-reviewed medical technology on the available evidence base to support uptake in clinical practice. Seven hundred thirteen new gastrointestinal devices were FDA approved or cleared between 2013 and 2023. The most frequent technologies had indications for use in general endoscopy (442 or 62.0% of all new technologies) with advanced endoscopy technologies being the second most common (172 or 24.1%). Ninety-nine new technologies had indications for use outside of the endoscopy suite. Ninety-nine percent of new technologies were FDA cleared against existing technologies through the 510(k) pathway rather than approved on new clinical data. Among the 19 devices with clinical trial data, trials were limited in sample size and generally evaluated disease-related changes or technical success rather than patient-reported outcomes that anchor drug trials. Twelve devices (63.2%) had favorable, published cost-effective data. To promote evidence-based discussion and uptake of new technology, and especially disruptive or high-risk technology, we propose a practical framework informed by balancing probable efficacy and safety and considering cost-effectiveness.</p>","PeriodicalId":7608,"journal":{"name":"American Journal of Gastroenterology","volume":" ","pages":""},"PeriodicalIF":8.0,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143412970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}